The text starts here.

History

1936 Sakuragaoka Laboratory Co., Ltd., Eisai's predecessor, established as a limited partnership company.
1941 Nihon Eisai Co., Ltd. established in Honjo-machi, Saitama Prefecture.
1944 Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge on equal terms under the name of Nihon Eisai Co., Ltd.
1950 Contraceptive SAMPOON receives official approval from the Japanese government.
Cardiotonic drug NEOPHYLLIN launched in Japan.
1952 Vitamin B1B2 supplement Chocola BB Tablets launched in Japan.
1955 Company name changed to Eisai Co., Ltd.
1957 Eisai launches its first mid-term plan under a three-year planning system that emphasizes innovation and strategic planning.
1961 Eisai listed on the first section of the Tokyo and Osaka Stock Exchanges.
Office established in Taiwan.
1964 Taiwan office obtains business license.
1966 Operations commence at Kawashima Industrial Park in Gifu Prefecture.
Founder Toyoji Naito named as Eisai's chairman; Yuji Naito succeeds as president.
1969 Pharmaceutical import subsidiary established in Taiwan.
1970 Pharmaceutical manufacturing and sales subsidiary established in Indonesia.
Toyoji Naito resigns as chairman and assumes the sole of honorary chairman.
1971 Naito Museum of Pharmaceutical Science and Industry, the first museum in Japan dedicated to medicine, opens in Gifu Prefecture.
1973 Pharmaceutical sales subsidiary established in Taiwan.
1974 Pharmaceutical sales subsidiaries established in Malaysia and the Philippines.
Metabolic cardiotonic drug NEUQUINON launched in Japan.
1977 Natural vitamin E supplement JUVELUX launched in Japan.
1978 Peripheral neuropathy treatment METHYCOBAL launched in Japan.
1979 Sales support and management services company established in Singapore.
1981 Chemical and pharmaceutical machinery sales subsidiary established in California, United States.
Operations commence at the Misato Plant in Saitama Prefecture.
1982 Tsukuba Research Laboratories completed in Ibaraki Prefecture.
1983 Eisai Chemical Co., Ltd.(Currently: Kashima Plant) established in Kashima, Ibaraki Prefecture to manufacture active pharmaceutical ingredients (APIs).
1984 Gastritis/gastric ulcer treatment SELBEX launched in Japan.
1987 Three-year mid-term planning system abolished in favor of a new five-year strategic plan.
Eisai Research Institute of Boston, Inc. established in Massachusetts, United States as a discovery research subsidiary.
1988 Yuji Naito named as Eisai's chairman; Haruo Naito succeeds as president.
Clinical research subsidiary established in New Jersey, United States.
Clinical research subsidiary established in London, United Kingdom.
1989 Pharmaceutical machinery manufacturing and sales subsidiary established in Cologne, Germany.
Chemical sales subsidiary established in London, United Kingdom.
Pharmaceutical sales subsidiary established in Thailand.
1990 Eisai London Research Laboratories, Ltd. established at the University of London in the United Kingdom as a discovery research subsidiary.
1991 Pharmaceutical sales subsidiary established in Hong Kong.
Representative office opened in Beijing, China.
Pharmaceutical manufacturing and sales subsidiary established in Shenyang, China.
Eisai celebrates its 50th anniversary.
1992 Holding company established in New Jersey, United States.
Eisai London Research Laboratories, Inc. opens in the United Kingdom, establishing a multipolar R&D network in Asia, America and Europe.
1995 Pharmaceutical sales subsidiaries established in the United States(North Carolina), the United Kingdom(London), and Germany(Frankfurt).
1996 Pharmaceutical sales subsidiary established in Paris, France.
Pharmaceutical manufacturing and sales subsidiary established in Suzhou, China.
Elmed Eisai Co., Ltd. established as a value-added generics sales subsidiary in Japan.
1997 KAN Research Institute Inc., specializing in bioscientific research, established in Kobe, Hyogo Prefecture.
Pharmaceutical sales subsidiary established in Seoul, South Korea.
Process research and pharmaceutical manufacturing facility completed in North Carolina, United States.
Alzheimer's disease treatment ARICEPT launched in the United States, the United Kingdom and Germany.
Proton pump inhibitor PARIET launched in Japan.
1998 Alzheimer's disease treatment ARICEPT launched in France.
Proton pump inhibitor PARIET launched in the United Kingdom and Germany.
1999 Proton pump inhibitor ACIPHEX (product name in Japan: PARIET) launched in the United States.
Alzheimer's disease treatment ARICEPT launched in Japan.
2001 Pharmaceutical sales subsidiary established in Madrid, Spain.
2002 Clinical research subsidiary established in New Jersey, United States.
2004 Eisai adopts “Company with Committees System”
Pharmaceutical sales subsidiary established in Mumbai, India.
Holding company established in London, United Kingdom.
2005 Corporate philosophy is added to Articles of Incorporation.
Pharmaceutical subsidiaries established in Italy(Milan), Switzerland(Zurich) and Sweden(Stockholm).
2006 Eisai launches the “Dramatic Leap Plan,” the Company's fifth mid-term strategic plan.
Clinical research and pharmaceutical sales subsidiaries established in Singapore.
Eisai acquires the exclusive rights to four oncology-related products from U.S. biotechnology company Ligand Pharmaceuticals Inc.
Pharmaceutical sales subsidiary established in Lisbon, Portugal.
2007 Pharmaceutical manufacturing subsidiary established in Hertfordshire, United Kingdom.
Eisai acquires U.S. bioventure company Morphotek, Inc.
API/formulation manufacturing and R&D subsidiary established in Andhra Pradesh, India.
Pharmaceutical sales subsidiary established in Brussels, Belgium.
2008 Eisai acquires U.S. biopharmaceutical company MGI PHARMA, INC.
Subsidiary to provide marketing support and maintenance services for pharmaceutical machinery established in Shanghai, China.
Rheumatoid Arthritis Treatment HUMIRA launched in Japan.
2009 Pharmaceutical sales subsidiary established in Vienna, Austria.
European Knowledge Centre established in the United Kingdom as Eisai's European strategic base.
New “Eisai Product Creation Systems (EPCS)” organizational structure launched.
Regional office opens in Bahrain.
Eisai Knowledge Centre, India opens as a global manufacturing and process research base in Andhra Pradesh, India.
2010 Eisai completes acquisition of U.S. biopharmaceutical company AkaRx, Inc.
Operations commence at the Koishikawa Knowledge Center, Tokyo.
Pharmaceutical sales subsidiary established in Canada.
New “Eisai Demand Chain Systems (EDCS)” organizational structure launched.
Aricept 23 mg tablet launched in the United States.
Pharmaceutical trading subsidiary established in China.
Anticancer agent HALAVEN Injection launched in the United States.
ARICEPT composition of matter patent expires in the United States.
H3 Biomedicine Inc. established in the United States.
2011 Mid-term Strategic Plan “HAYABUSA” launched.
Pharmaceutical sales subsidiary established in Brazil.
Anticancer agent HALAVEN Injection launched in Japan, Singapore and the European Union (EU).
Pharmaceutical sales subsidiary established in Mexico.